[THE INVESTOR]
Bukwang Pharmaceutical ’s subsidiary Dyna Therapeutics has clinched a deal with Denmark’s Solural Pharma for its new anti-cancer drug, the company said on June 30.
 |
Solural Pharma |
Dyna Therapeutic attained the exclusive rights to develop and sell SOL-804, which is used for the treatment of castration-resistant prostate cancer, around the world.
“Bukwang is continuously pursuing to develop new medicine and the establishment of Dyna is part of that effort,” an official of the company said. “Dyna, which specializes in developing a compatible dosage form (for drugs), is a great fit to develop SOL-804.”
By Ahn Sung-mi (
sahn@heraldcorp.com)
